Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Agalsidase beta - Sanofi Genzyme

Drug Profile

Agalsidase beta - Sanofi Genzyme

Alternative Names: Fabrazyme; Recombinant human α-galactosidase A - Sanofi Genzyme

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Canada; Genzyme Corporation
  • Developer Genzyme Canada; Icahn School of Medicine at Mount Sinai; Sanofi Genzyme
  • Class Galactosidases; Glycoproteins; Isoenzymes
  • Mechanism of Action Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fabry's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fabry's disease

Most Recent Events

  • 01 Dec 2019 Registered for Fabry's disease in China (IV)
  • 24 Jun 2018 Biomarkers information updated
  • 17 Aug 2017 Discontinued - Phase-III for Fabry's disease (Early-stage disease, In adolescents, In children, Treatment-naive) in Norway, Netherlands, Canada, Brazil, Argentina, Poland, United Kingdom, Czech Republic, France and USA (IV), because not listed on Sanofi Genzyme pipeline, August 2017
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top